Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enanta Pharmaceutica (NQ: ENTA )

24.89 +0.03 (+0.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 129,061
Open 24.82
Bid (Size) 9.920 (2)
Ask (Size) 33.00 (1)
Prev. Close 24.86
Today's Range 24.41 - 25.02
52wk Range 23.03 - 76.36
Shares Outstanding 21,055,392
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Enanta Shares Are Plunging Today
Enanta Pharmaceuticals Inc's (NASDAQ: ENTA) investigational COVID-19 pill, EDP-235, met its primary endpoints of safety and tolerability in its Phase 2 SPRINT trial but yielded  
Via Benzinga
Gold Edges Higher; PayPal Shares Tumble Despite Upbeat Earnings
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 50 points on Tuesday. The Dow traded down 0.01% to 33,616.00 while the NASDAQ fell 0.43% to... 
Via Benzinga

Performance

YTD
-45.60%
-45.60%
1 Month
-26.73%
-26.73%
3 Month
-47.71%
-47.71%
6 Month
-39.48%
-39.48%
1 Year
-36.94%
-36.94%

More News

Read More
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Crude Oil Down 1%; Under Armour Earnings Top Views
Via Benzinga
Expert Ratings for Enanta Pharma
Via Benzinga
Enanta Pharma Earnings Preview
Via Benzinga
Expert Ratings for Enanta Pharma
Via Benzinga
Enanta Pharmaceuticals's Earnings: A Preview
Via Benzinga
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Enanta Pharmaceuticals to Participate in Two Investor Conferences in May
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2023
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Presents Data for its COVID-19 and Respiratory Syncytial Virus Programs at the 33rd European Congress of Clinical Microbiology and Infectious Diseases
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
From Enanta Pharmaceuticals, Inc.
Via Business Wire
10 Companies That Had Tons of Money in SVB When It Collapsed
Via InvestorPlace
Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022
From Enanta Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.